A Phase 2 interventional study of LYN-005 in Schizophrenia Schizoaffective, sponsored by Lyndra Inc.. Completed at 5 sites in United States. Open to participants aged 18 Years to 50 Years. Per ClinicalTrials.gov, last updated 2023-02-08.
Sponsored by Lyndra Inc. · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 759 studies in Psychotic Disorders with a site in United States — 97 open to participants now, 113 under way, 7 of them phase 3. Psychotic Disorders · United States.
Among the 759 studies in Psychotic Disorders with a site in United States, this one is the 476th largest by enrollment of the 682 interventional ones that give a count, is one of 31 that started in 2020, is one of 85 in phase 2, and was the 596th registered.
1,589 studies on the registry are indexed under Psychotic Disorders; 281 are open to participants now.
Browse Psychotic Disorders studies →97 of the 759 studies in Psychotic Disorders with a site in United States are open now. Recruiting first, the newest first:
Washington University School of Medicine · Sites in United States
Ages 18–59 · Healthy volunteers
Washington University School of Medicine · Sites in United States
Ages 18–59 · Healthy volunteers
University of California, San Diego · Sites in United States
Ages 12–30
Case Western Reserve University · Sites in United States
Ages 18–50
VA Office of Research and Development · Sites in United States
Ages 18+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 204 Psychotic Disorders studies recruiting now, 53 (26%) set no upper age limit and 142 (70%) stop at 75 or younger; 50 take children under 18; 41 take healthy volunteers.
This study: 18 Years to 50 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
759 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 79 · Phase 2 110 · Phase 3 68 · Phase 4 121
First in 1984; this study’s year is marked. 31 started in 2020.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 34 is below the median of 65 across 1,322 interventional studies indexed under Psychotic Disorders.
Median enrollment 60 across the 682 interventional studies, 123 across the 67 observational. Of the 612 that completed or were terminated, 293 (48%) have results posted.
This tab as a report to print or save as PDF → With an account.
102 of 759 have an industry lead sponsor. The 10 most frequent:
Lyndra Inc. is the lead sponsor of 7 studies on the registry; none are open to participants now.
Lyndra Inc. has 3 studies filed under Psychotic Disorders — fewer than ten, so there is no comparison to draw.
41 of the studies in Psychotic Disorders with a site in United States that are under way reach primary completion within a year, 3 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06585787Phase 3Karuna Therapeutics, Inc., a Bristol Myers Squibb companyA Study to Evaluate KarXT as a Treatment for Psychosis Associated With Alzheimer's Disease (ADEPT-4) | 2026-11-24 |
| NCT04411225Phase 3University of California, San DiegoEffects of Cannabidiol (CBD) Versus Placebo as an Adjunct to Treatment in Early Psychosis | 2026-12 |
| NCT06482554Phase 3Louisiana State University Health Sciences Center ShreveportLumateperone for the Improvement of Apathy in Patients With Psychotic Symptoms. | 2026-12 |
| NCT05558332University of California, IrvineYouth Nominated Support Team | 2026-11 |
| NCT05457127University of California, San DiegoObstructive Sleep Apnea Treatment in Serious Mental Illness | 2026-11 |
Add all 41 to your calendar (.ics) → With an account.
Among the 759 studies in Psychotic Disorders with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Lyndra is developing an oral, extended release (ER) formulation of risperidone (LYN-005) presented in a capsule dosage form with the intent of reducing the frequency of dosing orally-administered medications to once weekly or less and thereby improving the management of schizophrenia.
Study LYN-005-C-004 will evaluate the safety, tolerability, and pharmacokinetics (PK) of multiple dose administration of the ER formulation at two dose levels of LYN-005 relative to IR risperidone.
LYN-005-C-004 is a blinded, multiple-dose, randomized, parallel group, safety, tolerability and PK study of LYN-005 in subjects with a primary diagnosis of schizophrenia or schizoaffective disorder in general good health. Eligible subjects must be clinically stable and receiving a therapeutic dose of an approved oral antipsychotic drug for a minimum of 6 weeks at the time of Screening. Enrolled subjects will be evaluated under steady-state conditions on commercially-available IR risperidone tablets and then assigned in blinded fashion either to LYN-005 weekly or continued encapsulated IR risperidone daily for 3 weeks to attain (or continue) steady-state exposure.
Inclusion Criteria: Eligibility for this study was met if each one of the following inclusion criteria was satisfied at Screening (or at baseline when specified):
The following psychiatric criteria were used to determine subject eligibility:
Exclusion Criteria: Subject will not be considered eligible to participate in this study if any one of the following exclusion criteria is satisfied at Screening (or at baseline when specified):
Subjects with known esophageal or GI disease, including but not limited to:
None = 0 no symptoms Mild = 1 awareness of symptom, but easily tolerated Moderate = 2 discomfort sufficient to cause interference with normal activities Severe = 3 incapacitating, with inability to perform normal activities.
Medical history or current diagnoses indicating the presence of any of the below conditions:
Use of the below medications/treatments in the 2 weeks before enrollment, including:
Medications that may interfere with the absorption, metabolism, or excretion of risperidone, e.g.:
Drugs metabolized via pathway, such as macrolide antibiotics and azole antifungals). Moderate or strong CYP3A4 p-glycoprotein (P-gp) enzyme inducers and inhibitors (carbamazepine, phenytoin, rifampicin, phenobarbital, itraconazole, verapamil). Moderate or strong CYP2D6 inhibitors (e.g., fluoxetine, fluoxetine combinations, paroxetine), or quinidine.
Subjects with clinically significant abnormal safety (e.g. physical examination, vital sign) or safety laboratory assessments, specifically:
Subjects with the below specified patterns of substance use at Screening:
Subjects of who are (hetero) sexually active but unwilling to use acceptable means of through the EOS. For clarity, subjects who are at least 1 year are not of reproductive potential. Acceptable means of contraception include:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.
Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.
Criteria about it usually ask for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
DSM diagnostic criteria
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
TIA (transient ischaemic attack)
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
CYP3A (CYP3A4) inhibitors and inducers
CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.
Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Creatinine clearance (CrCl)
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Reproductive potential
Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.
Criteria about it usually ask for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
LYN-005: capsules containing LYN-005 stellate; the 14mg dose of LYN-005 contains 3 active arms containing risperidone, and 3 inactive arms and the 28 mg dose of LYN-005 contains 6 active arms containing risperidone. AND IR Risperidone Matched Placebo: Orange capsule-shaped tablets containing inactive ingredient.
Drug: LYN-005
LYN-005 Matched Placebo: Size 00EL capsules containing inactive ingredient with no stellate. AND IR Risperidone: Risperidone 2 mg (orange) capsule-shaped tablets.
Drug: LYN-005
LYN-005 (14 or 28 mg weekly) plus IR risperidone matched placebo.
Also known as: Risperidone
Participants With at Least One Treatment Emergent Adverse Event (TEAE).
Incidence of treatment emergent adverse events (TEAEs) reported as participants with at least one treatment emergent adverse event (TEAE).
Time frame: 35 days
Total Number of Treatment Emergent Adverse Events (TEAEs).
Incidence of treatment emergent adverse events (TEAEs) reported as total number of TEAEs.
Time frame: 35 days
Active Moiety PK (Cmax)
Active moiety Cmax (risperidone and 9-hydroxyrisperidone combined) after repeat weekly doses of LYN-005 Extended Release (ER) capsules relative to Immediate Release (IR) risperidone tablets at 2 dose levels.
Time frame: Reported data was obtained following multiple dose administration of 3 weekly doses [(IR, Day-1), (ER, Week 1), ER Week 3)] of 14 or 28 mg risperidone LYN-005 capsules to assess extended release PK.
Active Moiety PK (AUC0-24, AUC0-168)
Active moiety AUC (risperidone and 9-hydroxyrisperidone combined) after repeat weekly doses of LYN-005 ER capsules relative to IR risperidone tablets at 2 dose levels.
Time frame: Reported data was obtained following multiple dose administration of 3 weekly doses [(IR, Day-1), (ER, Week 1), ER Week 3)] of 14 or 28 mg risperidone LYN-005 capsules to assess extended release PK.
Active Moiety Tmax
Active Moiety Tmax (h) (risperidone and 9-hydroxyrisperidone combined) after repeat weekly doses of LYN-005 ER capsules relative to IR risperidone tablets at 2 dose levels.
Time frame: Reported data was obtained following multiple dose administration of 3 weekly doses [(IR, Day-1), (ER, Week 1), ER Week 3)] of 14 or 28 mg risperidone LYN-005 capsules to assess extended release PK.
PK of Risperidone (Cmax).
To characterize exposure (Cmax) of risperidone during the switch to LYN-005.
Time frame: Reported data was obtained following multiple dose administration of 3 weekly doses [(IR, Day-1), (ER, Week 1), ER Week 3)] of 14 or 28 mg risperidone LYN-005 capsules to assess extended release PK.
PK of Risperidone (AUC0-24h, AUC0-168).
To characterize exposure (AUC0-24h, AUC0-168) of risperidone during the switch to LYN-005.
Time frame: Reported data was obtained following multiple dose administration of 3 weekly doses [(IR, Day-1), (ER, Week 1), ER Week 3)] of 14 or 28 mg risperidone LYN-005 capsules to assess extended release PK.
PK of 9-Hydroxyrisperidone (Cmax).
To characterize exposure (Cmax) of 9-Hydroxyrisperidone during the switch to LYN-005.
Time frame: Reported data was obtained following multiple dose administration of 3 weekly doses [(IR, Day-1), (ER, Week 1), ER Week 3)] of 14 or 28 mg risperidone LYN-005 capsules to assess extended release PK.
PK of 9-Hydroxyrisperidone (AUC0-24h, AUC0-168h).
To characterize exposure (AUC0-24h, AUC0-168h) of 9-Hydroxyrisperidone during the switch to LYN-005.
Time frame: Reported data was obtained following multiple dose administration of 3 weekly doses [(IR, Day-1), (ER, Week 1), ER Week 3)] of 14 or 28 mg risperidone LYN-005 capsules to assess extended release PK.
This study was conducted at 5 sites that randomized participants in the US. The study period was 13 August 2020 (first signed informed consent) to 22 December 2020 (last participant visit/observation)
| Milestone | LYN-005 14mg | LYN-005 28mg | Risperidone 2 mg | Risperidone 4 mg |
|---|---|---|---|---|
| Started | 12 | 12 | 4 | 4 |
| Completed | 9 | 11 | 4 | 3 |
| Not completed | 3 | 1 | 0 | 1 |
| Withdrew: Adverse event | 1 | 1 | 0 | 0 |
| Withdrew: Withdrawal by subject | 2 | 0 | 0 | 1 |
Incidence of treatment emergent adverse events (TEAEs) reported as participants with at least one treatment emergent adverse event (TEAE).
| Number of Participants with TEAEs | LYN-005 14mg | LYN-005 28mg | Overall LYN-005 | Risperidone 2 mg | Risperidone 4 mg | Overall Risperidone |
|---|---|---|---|---|---|---|
| Participants With at Least One Treatment Emergent Adverse Event (TEAE). | 10 | 8 | 18 | 1 | 1 | 2 |
Incidence of treatment emergent adverse events (TEAEs) reported as total number of TEAEs.
| Number of Experienced TEAEs | LYN-005 14mg | LYN-005 28mg | Overall LYN-005 | Risperidone 2 mg | Risperidone 4 mg | Overall Risperidone |
|---|---|---|---|---|---|---|
| Total Number of Treatment Emergent Adverse Events (TEAEs). | 15 | 21 | 36 | 2 | 2 | 4 |
Active moiety Cmax (risperidone and 9-hydroxyrisperidone combined) after repeat weekly doses of LYN-005 Extended Release (ER) capsules relative to Immediate Release (IR) risperidone tablets at 2 dose levels.
| ng/mL | LYN-005 14 mg (A) | LYN-005 14 mg (B) | LYN-005 14 mg (C) | Risperidone 2 mg (A) | Risperidone 2 mg (B) | Risperidone 2 mg (C) | LYN-005 28 mg (A) | LYN-005 28 mg (B) | LYN-005 28 mg (C) | Risperidone 4 mg (A) | Risperidone 4 mg (B) | Risperidone 4 mg (C) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Active Moiety PK (Cmax) | 31.0 ± 37.5 | 20.0 ± 56.7 | 18.6 ± 42.9 | 24.8 ± 38.3 | 30.3 ± 17.5 | 31.2 ± 68.7 | 24.6 ± 405.7 | 31.2 ± 32.1 | 30.4 ± 102.7 | 54.1 ± 19.3 | 46.3 ± 23.8 | 48.8 ± 40.9 |
Active moiety AUC (risperidone and 9-hydroxyrisperidone combined) after repeat weekly doses of LYN-005 ER capsules relative to IR risperidone tablets at 2 dose levels.
| h*ng/mL | LYN-005 14 mg (A) | LYN-005 14 mg (B) | LYN-005 14 mg (C) | Risperidone 2 mg (A) | Risperidone 2 mg (B) | Risperidone 2 mg (C) | LYN-005 28 mg (A) | LYN-005 28 mg (B) | LYN-005 28 mg (C) | Risperidone 4 mg (A) | Risperidone 4 mg (B) | Risperidone 4 mg (C) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| AUC0-24 | 377 ± 44.0 | 361 ± 49.0 | 371 ± 47.4 | 301 ± 23.1 | 326 ± 19.1 | 359 ± 32.6 | 472 ± 137.7 | 575 ± 39.3 | 568 ± 104.3 | 732 ± 46.3 | 753 ± 44.9 | 687 ± 36.9 |
| AUC0-168 | — | 1820 ± 52.1 | 2120 ± 53.2 | — | — | — | — | 3350 ± 42.3 | 2950 ± 121.1 | — | — | — |
Active Moiety Tmax (h) (risperidone and 9-hydroxyrisperidone combined) after repeat weekly doses of LYN-005 ER capsules relative to IR risperidone tablets at 2 dose levels.
| hours | LYN-005 14 mg (A) | LYN-005 14 mg (B) | LYN-005 14 mg (C) | Risperidone 2 mg (A) | Risperidone 2 mg (B) | Risperidone 2 mg (C) | LYN-005 28 mg (A) | LYN-005 28 mg (B) | LYN-005 28 mg (C) | Risperidone 4 mg (A) | Risperidone 4 mg (B) | Risperidone 4 mg (C) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Active Moiety Tmax | 1.9 (0.0 to 4.0) | 23.7 (4.0 to 120.0) | 23.8 (0.0 to 72.0) | 3.0 (1.0 to 4.0) | 1.5 (1.0 to 2.0) | 3.0 (2.0 to 4.0) | 1.0 (0.6 to 7.9) | 24.1 (6.1 to 72.5) | 23.8 (0.0 to 169.0) | 2.1 (0.8 to 6.0) | 4.0 (1.1 to 6.1) | 2.0 (2.0 to 2.1) |
To characterize exposure (Cmax) of risperidone during the switch to LYN-005.
| ng/mL | LYN-005 14 mg (A) | LYN-005 14 mg (B) | LYN-005 14 mg (C) | Risperidone 2 mg (A) | Risperidone 2 mg (B) | Risperidone 2 mg (C) | LYN-005 28 mg (A) | LYN-005 28 mg (B) | LYN-005 28 mg (C) | Risperidone 4 mg (A) | Risperidone 4 mg (B) | Risperidone 4 mg (C) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| PK of Risperidone (Cmax). | 11.7 ± 58.2 | 4.44 ± 95.3 | 4.07 ± 59.1 | 9.97 ± 111.0 | 12.3 ± 40.5 | 15.6 ± 84.2 | 21.2 ± 55.6 | 6.87 ± 72.7 | 7.39 ± 230.9 | 17.0 ± 21.2 | 13.5 ± 32.6 | 14.0 ± 33.0 |
To characterize exposure (AUC0-24h, AUC0-168) of risperidone during the switch to LYN-005.
| h*ng/mL | LYN-005 14 mg (A) | LYN-005 14 mg (B) | LYN-005 14 mg (C) | Risperidone 2 mg (A) | Risperidone 2 mg (B) | Risperidone 2 mg (C) | LYN-005 28 mg (A) | LYN-005 28 mg (B) | LYN-005 28 mg (C) | Risperidone 4 mg (A) | Risperidone 4 mg (B) | Risperidone 4 mg (C) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| AUC0-24h | 54.9 ± 81.5 | 65.8 ± 93.3 | 65.2 ± 66.6 | 43.4 ± 131.2 | 47.7 ± 103.5 | 86.2 ± 58.1 | 113 ± 109.9 | 111 ± 88.1 | 119 ± 257.4 | 87.1 ± 67.2 | 82.4 ± 67.0 | 84.4 ± 80.5 |
| AUC0-168 | — | 227 ± 87.3 | 306 ± 67.1 | — | — | — | — | 806 ± 91.2 | 453 ± 276.8 | — | — | — |
To characterize exposure (Cmax) of 9-Hydroxyrisperidone during the switch to LYN-005.
| ng/mL | LYN-005 14 mg (A) | LYN-005 14 mg (B) | LYN-005 14 mg (C) | Risperidone 2 mg (A) | Risperidone 2 mg (B) | Risperidone 2 mg (C) | LYN-005 28 mg (A) | LYN-005 28 mg (B) | LYN-005 28 mg (C) | Risperidone 4 mg (A) | Risperidone 4 mg (B) | Risperidone 4 mg (C) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| PK of 9-Hydroxyrisperidone (Cmax). | 20.8 ± 31.0 | 16.1 ± 49.6 | 15.6 ± 41.9 | 15.5 ± 12.1 | 17.5 ± 37.8 | 16.9 ± 53.3 | 16.0 ± 282.3 | 24.7 ± 26.0 | 22.5 ± 91.1 | 39.6 ± 22.9 | 35.7 ± 24.5 | 36.2 ± 38.4 |
To characterize exposure (AUC0-24h, AUC0-168h) of 9-Hydroxyrisperidone during the switch to LYN-005.
| h*ng/mL | LYN-005 14 mg (A) | LYN-005 14 mg (B) | LYN-005 14 mg (C) | Risperidone 2 mg (A) | Risperidone 2 mg (B) | Risperidone 2 mg (C) | LYN-005 28 mg (A) | LYN-005 28 mg (B) | LYN-005 28 mg (C) | Risperidone 4 mg (A) | Risperidone 4 mg (B) | Risperidone 4 mg (C) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| AUC0-24h | 315 ± 39.7 | 268 ± 38.2 | 302 ± 47.0 | 243 ± 11.2 | 262 ± 20.8 | 265 ± 26.6 | 268 ± 272.6 | 441 ± 33.6 | 523 ± 177.9 | 641 ± 43.5 | 665 ± 42.9 | 645 ± 45.5 |
| AUC0-168h | — | 1530 ± 51.7 | 1770 ± 54.4 | — | — | — | — | 2720 ± 35.9 | 2090 ± 100.5 | — | — | — |
Collected over 35 days Double-blind Period consisted of the period between Day 1 to Day 35.. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| LYN-005 14 mg | 0/12 (0%) | 0/12 (0%) | 10/12 (83.3%) |
| LYN-005 28 mg | 0/12 (0%) | 0/12 (0%) | 8/12 (66.7%) |
| IR Risperidone 2 mg | 0/4 (0%) | 0/4 (0%) | 1/4 (25%) |
| IR Risperidone 4 mg | 0/4 (0%) | 0/4 (0%) | 1/4 (25%) |
| Event | LYN-005 14 mg | LYN-005 28 mg | IR Risperidone 2 mg | IR Risperidone 4 mg |
|---|---|---|---|---|
| NauseaGastrointestinal disorders | 2/12 | 3/12 | 0/4 | 0/4 |
| Abdominal PainGastrointestinal disorders | 1/12 | 3/12 | 0/4 | 0/4 |
| DiarrhoeaGastrointestinal disorders | 0/12 | 0/12 | 0/4 | 1/4 |
| Alanine Aminotransferase IncreasedInvestigations | 1/12 | 0/12 | 1/4 | 0/4 |
| Weight IncreasedInvestigations | 0/12 | 1/12 | 1/4 | 0/4 |
| AkathisiaNervous system disorders | 0/12 | 0/12 | 0/4 | 1/4 |
| Abdominal Pain UpperGastrointestinal disorders | 2/12 | 1/12 | 0/4 | 0/4 |
| Abdominal DiscomfortGastrointestinal disorders | 0/12 | 2/12 | 0/4 | 0/4 |
| VomitingGastrointestinal disorders | 0/12 | 2/12 | 0/4 | 0/4 |
| HeadacheNervous system disorders | 1/12 | 2/12 | 0/4 | 0/4 |
| Age, Continuous(years) | LYN-005 14 mg | LYN-005 28 mg | Risperidone 2 mg | Risperidone 4 mg | Total |
|---|---|---|---|---|---|
| Mean | 36.0 ± 6.24 | 34.3 ± 7.46 | 35.0 ± 7.12 | 43.5 ± 7.85 | 36.2 ± 7.28 |
| Sex: Female, Male(Participants) | LYN-005 14 mg | LYN-005 28 mg | Risperidone 2 mg | Risperidone 4 mg | Total |
|---|---|---|---|---|---|
| Female | 2 | 3 | 1 | 0 | 6 |
| Male | 10 | 9 | 3 | 4 | 26 |
| Race/Ethnicity, Customized(Participants) | LYN-005 14 mg | LYN-005 28 mg | Risperidone 2 mg | Risperidone 4 mg | Total |
|---|---|---|---|---|---|
| Race — Black or African American | 11 | 11 | 4 | 4 | 30 |
| Race — White | 1 | 1 | 0 | 0 | 2 |
| Body Mass Index (BMI)(kg/m^2) | LYN-005 14 mg | LYN-005 28 mg | Risperidone 2 mg | Risperidone 4 mg | Total |
|---|---|---|---|---|---|
| Mean | 29.57 ± 4.695 | 24.98 ± 4.476 | 26.48 ± 2.680 | 26.78 ± 6.086 | 27.11 ± 4.835 |
| ESRS Total Score at Baseline(units on a scale) | LYN-005 14 mg | LYN-005 28 mg | Risperidone 2 mg | Risperidone 4 mg | Total |
|---|---|---|---|---|---|
| Mean | 0.2 ± 0.58 | 0.6 ± 2.02 | 0 ± 0 | 0.8 ± 1.5 | 0.4 ± 1.36 |
| CGI-S Total Score at Baseline(units on a scale) | LYN-005 14 mg | LYN-005 28 mg | Risperidone 2 mg | Risperidone 4 mg | Total |
|---|---|---|---|---|---|
| Mean | 2.9 ± 0.51 | 3.0 ± 0.85 | 2.8 ± 0.50 | 3.3 ± 0.50 | 3.0 ± 0.65 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Aug 2020 to primary completion in Dec 2020, 4 months.
Results were first posted in Feb 2023, 2 years 1 month after primary completion.
Of 39 phase 2 interventional studies under Psychotic Disorders, half reached primary completion within 39 months of starting (the median), counting those still running; a quarter within 22 and three quarters within 53. This study's 4 months is below that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Dec 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Lyndra Inc.